Pharmacy

High-value clinical research marks gradual shift to India: Parexel

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Datanomics: Digital vs traditional in the race for e-pharmacy growth

Traditional pharmacists protest as online pharmacy firms dominate India's drug retail market, outpacing brick-and-mortar players in growth and funding

AIOCD to go ahead with May 20 strike despite states opting out of protest

AIOCD will continue with its proposed nationwide strike against online pharmacies despite several state retail pharmacy associations opting out of the protest

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Q3FY26 preview: Strong domestic sales to lift revenues for pharma firms

Strong domestic sales are expected to lift Q3FY26 pharma revenues by 8-11%, while US generic Revlimid impacts weigh on margins. Hospitals and diagnostics outperform, with 20-22% revenue growth

FDA observation to hit Lanreotide supply; Cipla may face earnings risk

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations

Engineering the future: India's opportunity in synthetic biology

The Union Cabinet's approval of the BioE3 policy is a landmark step in the right direction. But the window of opportunity is narrow

GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

RPG Life Sciences eyes GLP-1 entry, US market via plant acquisitions

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Novo Nordisk set to launch diabetes drug Ozempic in India this month

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight los

Apollo Pharmacy to add 2 stores a day to its network for next 5 years

Apollo Pharmacy has crossed the 7,000-store milestone and now plans to open two new outlets every day for five years, expanding its reach through physical stores and its Apollo 24|7 digital platform

Apollo Pharmacy targets 100 mn customers in 5 yrs, 2 new stores daily: CEO

Apollo Pharmacy plans to open two new stores every day, targeting to grow its customer base to 10 crore within the next five years, its CEO P Jayakumar said on Friday. The omni-channel pharmacy network, which has crossed the 7,000-store mark with the opening of its latest store in Ayodhya, Uttar Pradesh, aims to strengthen the neighbourhood pharmacy reach. "We will continue to expand by opening two new stores every day and grow our customer base to 100 million within the next five years, ensuring that the highest-quality medicines remain within everyone's reach," Jayakumar said in a statement. Apollo HealthCo operates Apollo Pharmacy that serves users across over 19,000 pin codes. Apollo HealthCo Executive Chairperson Shobana Kamineni said at present, Apollo Pharmacy serves over one million orders every day. "The 7,000-store milestone reflects the scale Apollo has built and the trust families place in us. We will continue to deepen access, strengthen India's neighbourhood pharmacy

Apollo Hospitals expects restructuring to conclude by Q4FY27: CFO

Apollo Hospitals CFO says the restructuring and listing of its digital and pharmacy businesses will be completed by the last quarter of FY27, after approvals from regulators including SEBI and NCLT.

Zepto expands into online pharmacy, promises 10-minute medicine delivery

Quick commerce platform Zepto on Thursday announced its entry into the online pharmacy segment with the launch of 'Zepto Pharmacy', promising medicine delivery within 10 minutes in select metropolitan areas. The service has been rolled out in specific locations across Mumbai, Bengaluru, Delhi-NCR, and Hyderabad, Zepto Co-Founder and CEO Aadit Palicha said in a post on LinkedIn. The launch follows a 12-month pilot phase focused on refining operations, he said. "Today, we're formally announcing the launch of Zepto Pharmacy - Medicines delivered in 10 minutes! Over the past 12 months, the team has worked tirelessly to perfect the customer experience, supply chain, and compliance at a small scale, and we want to grow it steadily from here. Our objective is to keep operational standards extremely high and not scale too rapidly, given the complexity of this category," he wrote. The move marks Zepto's expansion beyond its core 10-minute grocery delivery model, placing it in competition wi

Indian pharma market grows 7.9% in July, led by chronic therapies

Despite flat volumes, India's pharma market posted 7.9% growth in July on strong demand for chronic therapies like cardiac and diabetes; MAT turnover crossed Rs 2.3 trillion

Emcure Pharma shares gain as JM Financial initiates coverage; check target

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects

Delhi govt orders CCTV cameras in chemist shops to curb misuse of medicines

To prevent misuse of Schedule H, H1, and X drugs, the Delhi government directs all chemist shops to install CCTV cameras by July 31; the move follows 11th National Narcotics Coordination Portal meetin

CBI searches Pharmacy Council of India chief's home over irregularities

A preliminary enquiry by the CBI pointed to suspected manipulation in the inspection and recognition processes for pharmacy colleges across several states, PTI reported

Govt, industry hold talk on issues over marketing code for medical devices

Medical device companies raise issues with the DoP over UDMPMD norms related to disclosure of training expenses and restrictions on overseas training approvals

SastaSundar to invest Rs 150 crore in 2 yrs, aims turnaround in FY26

SastaSundar Ventures Ltd is in the process of investing Rs 150 crore over the next two years to strengthen its digital healthcare platform and warehousing infrastructure to make a turnaround and return to profit in FY'26, a company official said on Thursday. The investment will largely be funded through a Rs 145-crore capital pool, created from the Flipkart Health exit settlement and internal treasury income. The Kolkata-based online pharmacy ended its partnership with Flipkart Health earlier this year and relaunched its B2C platform under its own brand. "We are aiming to return to net profit in the current fiscal through strategic initiatives. We are focusing on the execution of these and capital-efficient growth to recover the company from a Rs 122 crore net loss in FY'25. "Out of the Rs 150 crore, about Rs 40 crore was deployed in FY'25, and the remaining Rs 110 crore will be invested in FY'26 and FY'27," SastaSundar Chairman B L Mittal told PTI. To tap into the rising demand f